Silexion Therapeutics Corp. (SLXN), a clinical-stage company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, reported first-quarter 2026 financial results and outlined progress in advancing its lead candidate SIL204 into Phase 2/3 clinical development for locally advanced pancreatic cancer.
For the quarter ended March 31, 2026, the company recorded a net loss of $2.7 million, compared with a net loss of $1.7 million in the same period of 2025, reflecting higher R&D and G&A expenses.
Research and development costs rose to $1.4 million, from $0.6 million, driven by toxicology studies, GMP manufacturing, and clinical trial preparations.
General and administrative expenses increased to $1.4 million, from $1.1 million, largely due to professional services and share-based compensation.
Cash and cash equivalents stood at $2.4 million as of March 31, 2026. Subsequent warrant exercises and equity transactions in May 2026 generated approximately $1.0 million in gross proceeds, raising shareholders' equity above Nasdaq's $2.5 million minimum requirement and restoring compliance with listing standards.
Pipeline Update
Silexion highlighted several milestones for SIL204, its next-generation siRNA therapy designed to silence mutated KRAS, a driver in about 90% of pancreatic cancers:
-Israeli Ministry of Health approval to initiate a Phase 2/3 trial in locally advanced pancreatic cancer, marking SIL204's transition into clinical-stage development.
-Clinical Trial Application submitted to Germany under the EU Clinical Trials Information System, with Germany serving as the Reporting Member State.
-Trial initiation planned for Q2 2026, beginning with a safety run-in cohort of approximately 18 patients, followed by expansion into a randomized cohort of approximately 166 patients. The study will evaluate SIL204 in combination with standard chemotherapy using dual-route administration (intratumoral plus systemic).
CEO Ilan Hadar described the developments as a "defining moment" in Silexion's evolution, noting the company's advancement from preclinical to clinical-stage development across two major regulatory jurisdictions.
The company implemented a 1-for-15 reverse stock split on July 28, 2025.
SLXN closed Tuesday's trading at $0.26, down 1.65%. In pre-market trading the stock is at $0.63, up 135.65%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.